全文获取类型
收费全文 | 226篇 |
免费 | 23篇 |
专业分类
儿科学 | 3篇 |
基础医学 | 42篇 |
临床医学 | 10篇 |
内科学 | 116篇 |
皮肤病学 | 2篇 |
外科学 | 8篇 |
眼科学 | 2篇 |
药学 | 6篇 |
肿瘤学 | 60篇 |
出版年
2023年 | 1篇 |
2022年 | 2篇 |
2021年 | 1篇 |
2020年 | 4篇 |
2019年 | 5篇 |
2018年 | 2篇 |
2017年 | 2篇 |
2016年 | 1篇 |
2015年 | 7篇 |
2014年 | 2篇 |
2013年 | 5篇 |
2012年 | 5篇 |
2011年 | 8篇 |
2010年 | 3篇 |
2009年 | 4篇 |
2008年 | 3篇 |
2007年 | 13篇 |
2006年 | 1篇 |
2005年 | 10篇 |
2004年 | 12篇 |
2003年 | 8篇 |
2002年 | 9篇 |
2001年 | 6篇 |
2000年 | 7篇 |
1999年 | 8篇 |
1998年 | 3篇 |
1997年 | 6篇 |
1996年 | 4篇 |
1995年 | 3篇 |
1994年 | 3篇 |
1993年 | 8篇 |
1992年 | 10篇 |
1991年 | 4篇 |
1990年 | 13篇 |
1989年 | 10篇 |
1988年 | 6篇 |
1987年 | 8篇 |
1986年 | 1篇 |
1985年 | 6篇 |
1984年 | 11篇 |
1983年 | 3篇 |
1982年 | 4篇 |
1981年 | 4篇 |
1980年 | 3篇 |
1979年 | 4篇 |
1978年 | 3篇 |
1977年 | 2篇 |
1976年 | 1篇 |
排序方式: 共有249条查询结果,搜索用时 15 毫秒
21.
Trentin L Frasson M Donella-Deana A Frezzato F Pagano MA Tibaldi E Gattazzo C Zambello R Semenzato G Brunati AM 《Blood》2008,112(12):4665-4674
Lyn, a tyrosine kinase belonging to the Src family, plays a key role as a switch molecule that couples the B-cell receptor to downstream signaling. In B-CLL cells, Lyn is overexpressed, anomalously present in the cytosol, and displays a high constitutive activity, compared with normal B lymphocytes. The aim of this work was to gain insights into the molecular mechanisms underlying these aberrant properties of Lyn, which have already been demonstrated to be related to defective apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Herein, Lyn is described to be in an active conformation as integral component of an aberrant cytosolic 600-kDa multiprotein complex in B-CLL cells, associated with several proteins, such as Hsp90 through its catalytic domain, and HS1 and SHP-1L through its SH3 domain. In particular, Hsp90 appears tightly bound to cytosolic Lyn (CL), thus stabilizing the aberrant complex and converting individual transient interactions into stable ones. We also demonstrate that treatment of B-CLL cells with geldanamycin, an Hsp90 inhibitor already reported to induce cell death, is capable of dissociating the CL complex in the early phases of apoptosis and thus inactivating CL itself. These data identify the CL complex as a potential target for therapy in B-CLL. 相似文献
22.
23.
Erika Falisi Monica Facco Francesco Maura Elisabetta Novella Ilaria Nichele Silvia Finotto Ilaria Giaretta Elisa Ave Omar Perbellini Nicola Guercini Maria Teresa Scupoli Livio Trentin Valentina Trimarco Antonino Neri Gianpietro Semenzato Francesco Rodeghiero Giovanni Pizzolo Achille Ambrosetti 《American journal of hematology》2013,88(4):277-282
The immunoglobulin heavy chain variable (IGHV) gene mutational status represents a major prognostic marker in chronic lymphocytic leukemia (CLL). Usually, the prognostic implications of IGHV gene analysis can be reliably ascertained but, occasionally, double productive rearrangements have been detected. Clinical presentation and biological features of such cases are unknown. Sixty patients with morphologically and phenotypically monoclonal CLL but double productive IGHV rearrangements were retrospectively identified by mRNA analysis from three Hematology Institutions. Clinical and biological features and survival of these 60 patients were compared with a control group of patients with CLL and single IGHV rearrangement. A prospective registry was used to assess the epidemiology of double productive IGHV among incidental patients with CLL. Using standard criteria to define IGHV‐mutated (M) or unmutated (U) cases, 39 of the 60 patients (65%) with double productive IGHV rearrangement had concordant status (23 MM, 16 UU), while 21 (35%) had discordant IGHV status. As compared with M patients, the MM ones had lower CD38 expression, more favorable cytogenetics and more indolent clinical behavior. Cases with UU had similar characteristics of U patients. Discordant cases presented with adverse prognostic features and had an aggressive clinical behavior requiring early treatment, similar to U patients. The prevalence of double IGHV was 3.1%. Patients with CLL with double concordant mutational status (MM or UU) have a clinical course similar to that of the corresponding single IGHV status, while those exhibiting discordant status represent a high risk population. This may help correct stratification within clinical trials. Am. J. Hematol. 88:277–282, 2013. © 2013 Wiley Periodicals, Inc. 相似文献
24.
L Trentin A Ambrosetti R Zambello C Agostini M Masciarelli F Vinante M Chilosi G Pizzolo G Cetto G Semenzato 《Leukemia research》1987,11(9):843-847
To further define the mechanisms responsible for the alpha-interferon (alpha-IFN) efficacy in the treatment of hairy cell leukemia (HCL), experiments were carried out to specify the cytotoxic events taking place following this type of therapy. Although an increased natural killer (NK) activity was demonstrable after alpha-IFN treatment, evidence has been provided that hairy cells were not specifically lysed either by fresh autologous/allogenic NK lymphocytes or by lymphokine activated killer (LAK) cells. This property could not be induced in vitro by alpha-IFN or by interleukin-2 (IL-2). Our data favour the hypothesis that the increase of NK cell activity observed following alpha-IFN therapy has not a direct antineoplastic effect but is likely to be of relevance for a non-specific enhancement of the host immune system. In alpha-IFN treated HCL this latter property may account for the better resistance to infections which usually represents the major cause of mortality in these patients. 相似文献
25.
Achille Ambrosetti Gianpaolo Nadali Fabrizio Vinante Maria Maddalena Ricetti Giuseppe Todeschini Lorella Morosato Donata de Sabata Ivo Andrea Bergamo Andreis Marco Chilosi Gianpietro Semenzato Giovanni Pizzolo 《International Journal of Clinical & Laboratory Research》1993,23(1-4):34-37
Summary The CD25 molecule, which corresponds to the p55 α chain of the interleukin-2 receptors, is strongly expressed by neoplastic
cells in hairy-cell leukemia and is released in large amounts in the soluble form which is detectable in serum. In order to
assess the reliability of the soluble interleukin-2 receptor as a disease marker in the management of patients with hairy-cell
leukemia, we investigated serum levels in 35 untreated patients and in 2 patients with the hairy-cell leukemia variant. In
21 of 35 patients soluble receptor levels were also monitored during and after recombinant interferon-α therapy. Clinical
and hematological parameters were also assessed. Soluble interleukin-2 receptor levels were extremely high at the time of
diagnosis in patients with typical hairy-cell leukemia [32,722±27,001 vs. 331±145 units/ml in controls (mean±SD)], but not
in patients with the leukemia variant. A progressive decrease in soluble interleukin-2 receptor levels paralleled the clinical
response to treatment, although normal values were never detected, even in patients who achieved an apparent complete remission.
After recombinant interferon-α discontinuation, disease recurrence was accompanied by a progressive increase to pre-treatment
soluble receptor levels. Overall, a close correlation was found between soluble interleukin-2 receptor values and total tumor
burden (r=0.84,P<0.001). On the basis of these data, soluble interleukin-2 receptor should be regarded as a key marker in the management of
patients with hairy-cell leukemia. 相似文献
26.
27.
28.
29.
G Semenzato L Trentin R Zambello C Agostini P Bulian F Siviero A Ambrosetti F Vinante M Prior M Chilosi 《Leukemia》1988,2(12):788-792
High levels of soluble IL-2 receptor (sIL-2R) are detectable in the serum of HCL patients. To determine the cell source of this molecule, we evaluated the presence of sIL-2R in the supernatants obtained from in vitro cultures of leukemic (hairy cell, HC) and non-leukemic lymphocytes from six untreated HCL patients and from an additional four patients under therapy with rIFN-alpha 2. We demonstrated that cultured HCs at resting conditions were able to spontaneously release the sIL-2R, whereas control enriched B cells did not. This phenomenon was present only when culturing HCs recovered from patients observed at the time of diagnosis but was not observed during treatment with rIFN-alpha 2. Following activation in vitro with a series of different stimulatory agents including BCGF, phorbol myristate acetate, and anti-human IgM antibody, cultured HCs increased their capability to shed the IL-2R molecules. On the other hand, the release of sIL-2R from enriched T cell populations from HCL patients did not significantly differ from the value obtained in controls. Taken together, these findings provide evidence that leukemic B cells represent the main source of sIL-2R in HCL patients and further emphasize the importance of evaluating this parameter as a relevant marker for monitoring the effectiveness of rIFN-alpha 2 therapy. 相似文献
30.